Article
Cytochrome P450 2C19*2 polymorphism in patients with stable coronary heart disease and risk for secondary cardiovascular disease events: results of a long-term follow-up study in routine clinical care.
BMC cardiovascular disorders - 27 Aug 2013
Rothenbacher Dietrich, Hoffmann Michael M, Breitling Lutz P, Rajman Iris, Koenig Wolfgang, Brenner Hermann
Abstract excerpt
BACKGROUND: CYP2C19*2 polymorphism is related to metabolizer phenotypes resulting in reduced effectiveness in converting the antiplatelet drug clopidogrel to active drug. An association of the genotype itself with adverse outcomes is discussed. We investigated the prognostic value of carriage of the CYP2C19*2 allele in a high risk group of patients with prevalent coronary heart disease (CHD) at baseline during...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.